Hyderabad/Delhi, 16 January: Biological E Limited (BE), a Hyderabad-based vaccines and pharmaceutical company, has made a significant stride in the global fight against Covid-19 with the announcement of the World Health Organisation (WHO) granting an Emergency Use Listing (EUL) to their Corbevax.
This is India’s first indigenous Covid-19 vaccine developed on a protein sub-unit platform. The Managing Director of BE, Mahima Datla, expressed confidence that the WHO EUL will not only help them in their current efforts but also pave the way for future development of Covid-19 vaccines.
The company’s commitment to providing affordable and accessible vaccines is evident through their supply of 100 million doses of Corbevax to the Indian government.
Datla also highlighted that while many companies dropped out of the vaccine development race, BE remained steadfast in their mission and is now working on a next-generation vaccine based on the XBB1.5 variant that conforms to WHO recommendations.
The approval of Corbevax for emergency use by the Drugs Controller General of India (DCGI) and its potential use as a booster shot for adults further solidifies BE’s contribution to the global vaccination efforts. With their focus on high-quality and affordable vaccines, BE is determined to make a positive impact in the fight against Covid-19.
